Case Based Panel Discussion 2019 - Progression Post ALK Inhibitor - Role For Combination Therapies?

dbrock's picture
Is there is a role for combination therapies like chemotherapy/Avastin and immunotherapy?
H. Jack West, MD, Founder, President and CEO
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.

Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center. Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.

The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, they discuss progression after success on Alk inhibitors, and if there is a role for combination therapies like chemo/Avastin and immunotherapy.



To join the conversation, visit



Video Language: 


Join the Conversation

Please feel free to offer comments and raise questions in our
discussion forums.

 Join The conversation